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Introduction {#sec001}
============

Antimicrobial resistance has become a serious threat worldwide due to the global emergence of new resistance mechanisms, and limited drugs available for treatment. Multidrug-resistant bacteria like extended spectrum β-lactamase (ESBL) and carbapenemase producing members of Enterobacteriaceae (CPE), along with methicillin resistant *Staphylococcus aureus* (MRSA), and vancomycin resistant *Enterococcus* (VRE) are emerging pathogens around the globe \[[@pone.0212042.ref001]\]. Infections by these organisms often end with grave clinical outcomes and consume much of the health-care resources. ESBLs are the enzymes produced by bacteria that degrade extended spectrum β-lactam antibiotics such as third-generation cephalosporins, which are extensively used for the treatment of several systemic infections. The high level of expression of co-resistance to other classes of non β-lactam antibiotics by ESBL-producing pathogens is a compounding factor \[[@pone.0212042.ref002]\].

Gastrointestinal colonization with ESBL-producing Enterobacteriaceae (ESBL-E) may serve as an important reservoir and source of infections \[[@pone.0212042.ref002],[@pone.0212042.ref003]\]. Such resistant gut flora can no longer be considered as innocent bystanders. There are several hundred specific ESBL-encoding genes. Clones harboring these genes are involved in global dissemination (<http://www.lahey.org/studies/webt.asp>). Most frequently found genes are *bla*~*CTX-M*~, *bla*~SHV~ and *bla*~TEM~ that are horizontally transferrable. The *bla*~CTX-M~ genes are divided into five phylogroups; CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9 and CTX-M-25 \[[@pone.0212042.ref003], [@pone.0212042.ref004]\]. The CTX-M-1 phylogroup includes CTX-M-15 which is the most prevalent globally, probably evolving towards causing a global pandemic due to its carriage by members of the Enterobacteriaceae family \[[@pone.0212042.ref005]\].

As is well known, the intestinal tract is a hub of many multidrug resistant pathogens, especially in immunocompromised patients in many developing countries where infection control practices are often inadequate. Immunocompromisation as in case of HIV infection characteristically causes intestinal mucosal damage, weakening the epithelial barrier, exposing the host to a broad range of microbial byproducts that, in a way could augment the progress of HIV \[[@pone.0212042.ref006]\]. The intestinal microbiota may take advantage of an opportunity due to the weakened immune system. Thus the burden of ESBL-E and their respective antimicrobial resistance patterns in any community whether healthy or immunocompromised have a definite impact on the health standard of that section of the population.

According to recent estimates, the global prevalence of ESBL carriage among Enterobacteriaceae in healthy individuals is around 14% \[[@pone.0212042.ref007]\], and Asia and Africa have experienced a tremendous increase in the numbers of ESBL-producing bacteria since the last decade. The high rate of the gut carriage in Indian and Chinese population probably accounting for the largest reservoirs of ESBL genes in Asia \[[@pone.0212042.ref002], [@pone.0212042.ref007]\].

The data on the gut colonization rate of ESBL producing bacteria in HPLWH are sparse, though Wilmore SMS, et al. recently found 13.7% prevalence of ESBL-E carriage in HIV-infected children in Zimbabwe \[[@pone.0212042.ref008]\]. In Nepal gut colonization of ESBL-E and CPE is not well documented. This cross-sectional study was conducted to determine and compare the rate of gastrointestinal carriage of ESBL-E and CPE in the HPLWH and healthy HIV negative population in western Nepal.

Methods {#sec002}
=======

Ethics statement {#sec003}
----------------

This study was approved by the Institutional Ethics Committee, Manipal Teaching Hospital, Pokhara, Nepal. Written informed consent was obtained from each individual participating voluntarily in the study.

Study design, site, and enrollment of participants {#sec004}
--------------------------------------------------

This cross-sectional study was conducted in nine districts of State 4 and State 5 of western Nepal. Sampling was performed between, July 2016 and January 2017. HPLWH were chosen from daycare center attendees and from those visiting Manipal Teaching Hospital and Western Regional Hospital, Pokhara for follow up. The enrolled study subjects comprised of all confirmed HIV sero-positive patients belonging to the above states ([Fig 1](#pone.0212042.g001){ref-type="fig"}), who volunteered to participate in the study. All participants were healthy without any signs and symptoms of infection including lymphadenopathy, fever, cachexia, unexplained diarrhea, cough, fatigue, and dizziness, as clinically evaluated by the physician, during the period of sample collection.

![Location of 2 States (4 and 5) of Nepal where samples were collected.\
(The star indicates samples from HPLWH, Blue star- ESBL negative and Red star- ESBL positive. Yellow area indicates samples collected from HIV sero-negative population in the community). Map source: <https://commons.wikimedia.org/wiki/Maps_of_the_world>.](pone.0212042.g001){#pone.0212042.g001}

The specimens from HIV negative healthy volunteers from the community were obtained from the same geographical area to which HIV positive subjects belonged, using cluster random sampling method. The study area (State 4 and State 5) was divided into 23 districts; the districts were further dived to 63 municipalities and 131 rural municipalities. Out of 23 districts, samples were collected from 11 as shown in [Fig 1](#pone.0212042.g001){ref-type="fig"}. All municipalities or rural municipalities of 11 districts were numbered according to alphabetic order and 10 municipalities were selected by random sample calculation using software [*http*:*//www*.*randomizer*.*org/form*.*htm*](http://www.randomizer.org/form.htm). On an average 32 houses were included per district and one fecal sample from one healthy volunteer per house was collected.

Specimen collection and questionnaire {#sec005}
-------------------------------------

Four hundred seventy-six specimens from HPLWH and HIV negative healthy volunteers from the community were screened for ESBL and CPE. A pilot study was carried out to determine the most suitable specimen collection method. Collecting stool specimen was found to be administratively cumbersome as it involved at least two visits (once to enroll the participant and handover the specimen transport container and the second time to retrieve the collected stool specimen). Contrary to that, rectal swab could be collected along with the enrollment on the same visit and hence was the specimen of choice.

A cotton swab pre-moistened with sterile normal saline was inserted 3-5cms into the rectum and gently rotated for few seconds. The swabs were placed in a tube containing w/0.1% peptone water (HIculture Transport Swab, Himedia, India). All specimens were transported to the microbiology laboratory in specimen transport containers with ice packs. The samples were processed within a maximum of 8 hours of collection, depending upon the distance between the laboratory and the place of visit. Detailed questionnaires ([S1 Questionnaires](#pone.0212042.s001){ref-type="supplementary-material"}) including those delineating demographic and clinical information were included. Persons on antibiotic therapy or with a recent history of antibiotic use and/or hospitalization 30 days prior to specimen collection were excluded.

Isolation and screening for ESBL-producing enterobacteriaceae {#sec006}
-------------------------------------------------------------

The rectal swab was placed in 1 ml of sterile 0.9% saline and then vortexed for 30 seconds. A small amount (10 μl) of the suspension was inoculated on commercial ESBL-selective chromogenic medium (HiMedia, India). Plates were incubated at 37°C under aerobic conditions and examined after 24 hours. The color of the colonies led to presumptive identification according to the reference color chart provided by the manufacturer. The identification was confirmed by standard biochemical tests for their speciation \[[@pone.0212042.ref009]\]. Screening for CPE was done on MacConkey agar with 1 μg/ml imipenem (HiMedia, India). All ESBL positive isolates were preserved in brain heart infusion-glycerol broth in stock vials and stored at -20°C for further study.

ESBL detection by phenotypic methodsThe double-disc synergy test {#sec007}
----------------------------------------------------------------

Strains grown on ESBL HiChrome agar were tested for ESBL production by the Double Disc Synergy Test (DDST) using Ceftazidime (30 μg) and ceftazidime + clavulanic acid (30 μg/10 μg) \[[@pone.0212042.ref010]\]. Supplies were obtained from Hi-Media Laboratories Pvt. Limited, Mumbai, India.

### AmpC detection {#sec008}

All the ESBL positive isolates resistant to cefoxitin in initial screening were confirmed for the AmpC enzyme co-production by two different methods (saline disc method and inhibitor-based tests) \[[@pone.0212042.ref011], [@pone.0212042.ref012]\]. Isolates which gave interpretably positive results by both the methods were considered as AmpC producers. *Klebsiella pneumoniae* ATCC 700603 and *E*. *coli* ATCC 25922 standard strains were used as positive and negative controls respectively.

### Antimicrobial susceptibility testing {#sec009}

Antibiotic susceptibility testing was performed by Kirby-Bauer disk diffusion method as per CLSI guidelines \[[@pone.0212042.ref010]\], using eight routinely used antibiotics against the common pathogens encountered in day to day clinical practices, (tetracycline (30μg), tigecycline (15μg), amoxicillin/clavulanic acid (30μg), cefoxitin (30μg), imipenem (10μg), ciprofloxacin (30μg), amikacin (30μg), and nitrofurantoin (300μg). *Escherichia coli* (ATCC 25922) and *Klebsiella pneumoniae* (ATCC 700603) were used as the quality control strains. Isolates either resistant or intermediately sensitive to drugs were categorized as non-susceptible. For tigecycline zone size ≥18mm was considered as susceptible.

Genotypic screening of ESBL phenotypes {#sec010}
--------------------------------------

Isolates displaying an ESBL phenotype were screened for ESBL encoding genes by multiplex PCR. The presence of β-lactamase genes *bla*~TEM~/*bla*~SHV~/*bla*~OXA-1~ and *bla*~CTX-M~ including phylogenetic groups 1, 2 and 9 were detected by two multiplex PCR assays \[[@pone.0212042.ref013]\]. Isolates positive for phylo-group1 were further characterized for CTX-M 15 gene by singleplex PCR \[[@pone.0212042.ref014]\].DNA isolation was performed by commercially available DNA purification kit (HipurAbacterial genomic DNA purification Kit, Himedia, India). PCR reactions were carried out in 25 μl volumes. This included 2 X Amplicon III Red Taq master mixes consisting of Tris HCL pH 8.5, (NH4)~2~ SO~4~, 4 mM MgCl~2~, 0.2% Tween 20, 0.4 mM dNTPs, and 0.2 units/μl amplicon Taq DNA polymerase. The primers were used between 0.2μM to 0.4 μM concentrations. The template was used in 1μl volume. The primers and the size of the expected DNA products for each enzyme group as previously described are listed in supplement file: [S1 Table](#pone.0212042.s002){ref-type="supplementary-material"}.

Statistical analysis {#sec011}
--------------------

Prevalence of ESBL producing isolates along with the corresponding 95% CI stratified by age group is presented by calculating frequencies and percentages. Chi-square test was used with appropriate correction for the observation. Binary logistic regression analysis was used to identify risk factors for colonization by ESBL-E. The results were presented as OR with 95% CI. Significance was set at p\<0.05. Statistical analyses were performed using SPSS Statistics (IBM Corporation, Somers, NY) software, version 22.0. p\< 0.05 were considered to be statistically significant.

Results {#sec012}
=======

Demographics and clinical parameters {#sec013}
------------------------------------

Specimens were collected from 119 HPLWH (82 females and 37 males). The median age of the subjects was 31 (inter-quartile range (IQR 14--43) years. The median duration of antiretroviral therapy (ART) was 3 years (IQR 2--4). Specimen from 357 healthy volunteers (213 female and 144 male) from the community with median age 28 (inter-quartile range (IQR 9--53) years were also obtained.

ESBL-E carriage rate in HPLWH and healthy participant {#sec014}
-----------------------------------------------------

ESBL-E were isolated in 45 (37.82% \[CI 29.09, 47.16\]) and 246 (68.91% \[CI63.93, 73.49\]) HPLWH and healthy participant respectively. One HPLWH yielded two ESBL isolates (*E coli* and *Klebsiella*). HPLWH had lower fecal ESBL carriage rate (odds ratio 0.274 \[CI 0.178, 0.423\]) compared to healthy subject's (p\<0.01). Among healthy subjects, higher ESBL carriage was observed in those who had close livestock contact and had easy access to over-the-counter (OTC) medicines (both prescription and non prescription drugs including antibiotics: oral or parenteral), compared with those who did not have close contact with livestock and no history of medication OTC{(73.3% versus 26.7%, P = 0.001) and (74.7 versus 25.3%, p = 0.001), respectively; [Table 1](#pone.0212042.t001){ref-type="table"}}.Study subjects with varying demographic and related factors, such as ART duration, CD~4~ count, occupation, hospital admission, international travel, food habit, history of recent antibiotic use did not obviate differing ESBL-E colonization rates.

10.1371/journal.pone.0212042.t001

###### Demographic and clinical characteristics in PLWH and healthy subjects.

![](pone.0212042.t001){#pone.0212042.t001g}

                                                                       PLWH              Healthy subjects                                          
  -------------------------------------------------------------------- ----------------- ------------------ ------------ ------------ ------------ -----------
  **Total participants (n = 119+357 = 476)**                           45 (37.82)        74(63)             \-           246 (68.9)   111(31.1)    **-**
  **Gender**                                                                                                0.219                                  0.518
  Male                                                                 17(45.9)          20(54.1)           102(70.8)    42(29.2)                  
  Female                                                               28(34.1)          54(65.9)           144(67.6)    69(32.4)                  
  **Age**                                                                                                   0.620                                  0.751
  \</ = 18                                                             15(34.9)          28(65.1)           113(68.1)    53(31.9)                  
  \>18                                                                 30(39.5)          46(60.5)           133(69.6)    58(30.4)                  
  Median Age (IQR) years                                               33\[14.5,43.5\]   28\[14,42\]        \-           31\[9,50\]   28\[8,55\]   \-
  **ART**                                                                                                   0.852        NA           NA           NA
  Yes                                                                  39(37.5)          65(62.5)                                                  
  No                                                                   6(40)             09(60)                                                    
  **Duration of ART**                                                                                       0.270        NA           NA           NA
  **\< = 18**                                                          11(47.8)          12(52.2)                                                  
  **\>18**                                                             34(35.4)          62(64.6)                                                  
  Median duration of ART (IQR) years                                   3\[1.5, 4.5\]     3\[2,4\]                                                  
  **Occupation**                                                                                            0.75                                   **0.03**
  Agriculturist                                                        21 (38.9)         33 (61.1)          120 (71.4)   48 (28.6)                 
  Study                                                                15 (40.5)         22 (59.5)          86 (76.8)    26 (23.2)                 
  Business/job                                                         06 (30)           14 (70)            24 (63.2)    14(36.8)                  
  Others                                                               02 (25)           06 (75)            18 (51.4)    17 (48.6)                 
  **Clinical Characteristics** Admitted to hospital in last 6 months                                        0.063        NA           NA           NA
  Yes                                                                  6(66.7)           3(33.3)                                                   
  No                                                                   39(35.5)          71(64.5)                                                  
  **History of Antibiotic use (6 months)**                                                                  0.917        NA           NA           NA
  Yes                                                                  4((36.4)          7(63.6)                                                   
  No                                                                   41(38)            67(62)                                                    
  **CD4 count (cells/ /mm3)**                                                                               0.816        NA           NA           NA
  \<350                                                                2(33.3)           4(66.7)                                                   
  \>/ = 350                                                            43(38.1)          70(61.9)                                                  
  **Animal contact (domestic and livestock)**                                                               0.762                                  **0.001**
  Yes                                                                  25(39.1)          39(60.9)           198(73.3)    72(26.7)                  
  No                                                                   20(36.4)          35(63.6)           48(55.2)     39(44.8)                  
  **OTC medicine use**                                                                                      0.055                                  **0.001**
  Yes                                                                  30(45.5)          36(54.5)           195(74.7)    66(25.3)                  
  No                                                                   15 (28.3)         38(71.7)           51 (53.1)    45(46.9)                  
  **International travel within the last 12 months**                                                        0.63                                   0.52
  Yes                                                                  02(28.6)          05(71.4)           08(11.6)     05(88.4)                  
  No                                                                   42(37.5)          70(62.5)           240(69.8)    104(30.2)                 
  **Food habit**                                                                                            0.84                                   0.53
  Vegetarian                                                           04(9%)            06(8)              18(64.3)     10(35.7)                  
  Non-vegetarian                                                       40(91%)           69(92)             230(69.9)    99(30.1)                  

Antibiotic resistance pattern among ESBL-E isolates {#sec015}
---------------------------------------------------

Antibiotic resistance pattern of ESBL producing bacteria isolated from HIV positive and healthy subjects are summarized in [Fig 2](#pone.0212042.g002){ref-type="fig"}. Of all ESBL-producing Enterobacteriaceae obtained both from HPLWH and healthy community subjects, co-resistance to amoxicillin-clavulanate was found in 80.4%, 70.7% of the isolates, to ciprofloxacin in 45.6%, 56.1% isolates, amikacin 4.3%, 17.1% isolates, tetracycline 73.9%, 52.8% isolates, cefoxitin 80.4%, 64.2% isolates, and nitrofurantoin in 6.5%, 31.3% isolates respectively. All ESBL-E isolates were, susceptible to tigecycline and imipenem.

![Antibiotic susceptibility and ESBL related genes identified in 292 ESBL producing isolates.](pone.0212042.g002){#pone.0212042.g002}

### AmpC and carbapenemase producers among ESBL-E isolates {#sec016}

AmpC co-production was observed in ESBL positive isolates in both the study groups. The co-production of ESBL and AmpC was higher in HPLWH as compared to the healthy community group (49%;22/45), and (42.2%;104/246) respectively ([Table 1](#pone.0212042.t001){ref-type="table"}). In this study, no carbapenemase producing Enterobacteriaceae was isolated.

### ESBL enzyme type prevalence {#sec017}

All 46 ESBL-producing Enterobacteriaceae isolated from 45 HPLWH were confirmed by PCR ([Fig 2](#pone.0212042.g002){ref-type="fig"}). Ten (22.2%) of these isolates showed genes coding simultaneously for multiple enzymes in various combinations while 36 (78.3%) isolates were carrying genes encoding a single enzyme. Of the 46 ESBL-producing strains, 11 (23.9%) were identified as producers of TEM-type, 4 (8.7%) of OXA-1-type and 7 (15.2%) of SHV-type β-lactamases. Among 40 (86.9%) CTX-M-producing strains, 29 (63%) and 11 (23.9%) were identified to be producing CTX-M phylogroups 1 and 9, respectively. The gene coding for the phylogroup 2 was not observed in any of the isolates. The uniplex PCR for CTX-M phylogroups-1strains revealed that 28/29 (96.6%) isolates were of blaCTX-M-15 ESBL type.

Out of 246 phenotypically confirmed ESBL-producing Enterobacteriaceae from healthy participants, 242 (98.4%) were confirmed by PCR ([Fig 2](#pone.0212042.g002){ref-type="fig"}). Forty-five (18.6%) of these isolates showed genes coding simultaneously for multiple enzymes in various combinations while 197 (81.4%) isolates were carrying genes coding for single type of enzyme. Of the 242 ESBL-isolates, 45 (18.6%) were positive for TEM-type, 15 (6.2%) as OXA-1-type and 47(19.4%) as SHV type β-lactamases. Among 200 (82.6%) CTX-M-producing strains, 174(87%), and 26(13%) isolates belonged to CTX-M phylogroups 1 and 9 respectively. All of 174(100%) CTX-M phylogroups 1 were identified as the blaCTX-M-15. The gene coding for the phylogroup 2 was not observed in any of the isolates. The dominant species among ESBL-E from both HPLWH and healthy participant groups were *E*. *coli* (37/46, 80.4%; 206/246, 83.7%), followed by *K*. *pneumoniae* (6/46, 13%; 32/246, 13%). In addition, *Enterobacter* species (1/46, 2.2%; 3/246, 1.2%), *K*. *oxytoca* (2/46, 4.4%; 2/246, 0.8%), and *Citrobacter* spp. (0/46, 00%; 3/246, 1.2%), were found among the ESBL producers.

Predictors of ESBL carriage {#sec018}
---------------------------

In this study, univariate and multivariate logistic regression model was used to analyze risk factors associated with ESBL colonization ([Table 2](#pone.0212042.t002){ref-type="table"}). Among the HPLWH the odd of ESBL carriage was 1.537 times (95% CI 0.349, 6.762) higher in those on ART than in those without ART. Among the HPLWH taking antibiotics, there was a 21% \[0.787 (95% CI 0.179, 3.464)\] odds reduction of ESBL carriage rate. In addition, the odd of ESBL carriage in HPLWH were 3.638 times (0.793, 16.68) higher in those admitted to hospital in the previous six months.

10.1371/journal.pone.0212042.t002

###### Univariate and multivariate analysis of factors associated with ESBL-E carriage.

![](pone.0212042.t002){#pone.0212042.t002g}

                                                                       PLWH(n = 119)           Healthy subjects (n = 357)                                                                                                
  -------------------------------------------------------------------- ----------------------- ---------------------------- --------------------- --------------------- --------------------- --------------------- ---- ----
  **Gender**                                                                                   0.221                                                                                          0.518                      
  **Male**                                                             1.639 (0.743, 3.617)    1.867(0.796, 4.380)                                1.164(0.743, 1.843)   2.244(1.392, 4.511)                              
  **Female**                                                           1                       1                                                  1                     1                                                
  **Age**                                                                                      0.620                                                                                          0.751                      
  **\< = 18**                                                          1                       1                                                  1                     1                                                
  **\>18**                                                             1.217(0.559, 2.650)     1.281(0.515, 3.186)                                1.076(0.686, 1.685)   1.091(0.682, 1.746)                              
  **ART**                                                                                      0.852                                                                    NA                    NA                    NA   NA
  Yes                                                                  0.9 (0.298, 2.722)      1.535(0.334, 7.047)          1.537(0.349, 6.762)                                                                          
  No                                                                   1                       1                            1                                                                                            
  **ART duration**                                                                             0.273                                                                    NA                    NA                    NA   NA
  \< = 1                                                               1                       1                            1                                                                                            
  \>1                                                                  0.598(0.239, 1.499)     0.432(0.124, 1.505)          0.473(0.139, 1.614)                                                                          
  **Clinical Characteristics Admitted to hospital in last 6 months**                           0.79                                                                     NA                    NA                    NA   NA
  **Yes**                                                              3.641 (0.863, 15.366)   3.414(0.740, 15.750          3.638(0.793, 16.68)                                                                          
  **No**                                                               1                       1                            1                                                                                            
  **History of Antibiotic use (6 months)**                                                     0.917                                                                    NA                    NA                    NA   NA
  **Yes**                                                              0.934(0.257, 3.387)     0.703(0.156, 3.159)          0.787(0.179, 3.464)                                                                          
  **No**                                                               1                       1                            1                                                                                            
  **CD4 count (cells/mm**^**3**^ **)**                                                         0.817                                                                    NA                    NA                    NA   NA
  **\<350**                                                            0.814(0.143, 4.634)     1.008 (0.163, 6.237)         0.956(0.158, 5.785)                                                                          
  **\>/ = 350**                                                        1                       1                            1                                                                                            
  **Animal contact (domestic and livestock)**                                                  0.762                                                                                          0.002                      
  **Yes**                                                              1.122(0.533, 2.361)     1.073(0.447, 2.571)          1.153(0.515, 2.581)   2.234(1.353, 3.689)   2.244(1.301, 3.871)   1.866(1.109, 3.140)        
  **No**                                                               1                       1                            1                     1                     1                     1                          
  **OTC**                                                                                      0.050                                                                                          0.001                      
  **Yes**                                                              2.111(0.978, 4.557)     2.108(0.937, 4.740)          1.988(0.898, 4.401)   2.607(1.600, 4.249)   3.528(1.949, 6.388)   2.296(1.389, 3796)         
  **No**                                                               1                       1                            1                     1                     1                     1                          

We found significant rate of ESBL colonization among individuals who had close contact with livestock \[HPLWH study group OR 1.153 (95% CI 0.515, 2.581) as compared to healthy HIV negative group 1.866 (95%CI 1.109, 3.140) and also among individuals using medication over-the-counter \[HPLWH OR 1.988 (95%CI 0.898, 4.401) vs. the healthy HIV negative subjects 2.296 (95% CI 1.389, 3796). Majority of the participants were the frequent consumer of non-vegetarian diet and had no previous international travel history, therefore these variables were not included in the analysis. There was no significant association between ESBL-E carriage and gender, age, ART duration, antibiotic use, or CD4 count.

Discussion {#sec019}
==========

Prevalence of ESBL-carrying Enterobacteriaceae in the gut of healthy people has been reported globally, but there is little information about such prevalence and the risk factors thereof, among the HPLWH. Surveillance for gut colonization of ESBL-producing bacteria in humans provides information about the fecal flora which may contaminate the products entering the food chain. Limited availability of antibiotics for treating patients infected by ESBL and CPE producing bacteria represents a great concern for healthcare.

According to Woerther PL et al. \[[@pone.0212042.ref002]\] and the WHO 2010 population census (<http://www.who.int/research>), the number of ESBL-E carriers was estimated over 1.1 billion in Southeast Asia alone. The Western Pacific and Eastern Mediterranean regions rank second and third, with 280 and 180 million carriers, respectively, ahead of Africa, where 110 million carriers are estimated to be present. America and Europe appear to be far behind, with 48 and 35 million immunocompetent carriers, respectively. Few studies from Nepal reported that ESBL prevalence among clinical Enterobacteriaceae isolates ranged between 13 to 39% with CTX-M-15 being the predominant genotype \[[@pone.0212042.ref015]--[@pone.0212042.ref017]\]. Shrestha B, et al.found15% prevalence of carbapenemase-producing hospital strains of *E coli* encoding various NDM-Type-Metallo-β-Lactamases \[[@pone.0212042.ref018]\], but studies pertaining to gastrointestinal colonization rate and genotypic distribution of ESBL-E in either hospitalized patients or healthy subjects in Nepal are lacking. Healthy individuals at the community level are an important reservoir for ESBLs and the global report shows that colonization rate appears to be increasing over time (approx. \>5% annually) \[[@pone.0212042.ref002], [@pone.0212042.ref007]\]. The present study demonstrated a high rate (68.9%) of gut colonization by ESBL-E in healthy subjects from the community in western Nepal. Colonization rate seems to be quite higher in this geographical area compared to previous studies around the globe \[[@pone.0212042.ref001], [@pone.0212042.ref002], [@pone.0212042.ref015], [@pone.0212042.ref017]\]. Rates reported in a systematic review and meta-analysis by S Karanika, et al. in 2016 \[[@pone.0212042.ref007]\], showed that the global pooled prevalence of ESBL class A colonization was 14% (95% CI, 9, 20). The pooled prevalence was higher in Asia and Africa (ranging from 46%, (95% CI, 29, 63) to 15%, (95% CI, 4, 31) and lower but still significant in central (3%, 95% CI, 1, 5), northern (4%, 95% CI, 2, 6), and southern Europe (6%, 95% CI, 1, 12) and the Americas (2%, 95% CI, 0, 5).

Surprisingly, HPLWH in the present study showed low colonization rates of ESBL-E as compared to healthy subjects (37.8% v/s 68.9%). Padmavathy K, et al. while working on the virulence of uropathogenic *E coli* observed that ESBL producers were more common among HIVsero-negative patients compared to the HIV sero-positive study subjects (16.7% vs 3.9%, P = 0.04407).Contrary to this, multiple antibiotic resistance (ESBL+ AmpC+ fluoroquinolone) in her study, was significantly higher among the isolates from HIV positive patients compared to the HIV negative cohort (59.2% vs 19.0%, P = 0.000036) \[[@pone.0212042.ref019]\]. Much in agreement with the present study, Karol JM, et al. found a low rate of ESBL-E among the clinical isolates in HIV positive patients (p = 0.92, OR 1:1.04) \[[@pone.0212042.ref020]\].

Though, various studies in the past reported low ESBL carriage among the clinical isolates in HIV positive individuals, none of these studies have highlighted these aspects about the gut colonizers \[[@pone.0212042.ref008], [@pone.0212042.ref019], [@pone.0212042.ref020]\]. The exact modus operandi for such low colonization rate in HIV infected subjects is still conjectural. However, HIV patients are more prone to infections, and hence are more likely to be hospitalized and consume antimicrobial agents than HIV negative persons; a proposition that could support the view that HIV status might not always be a well-established risk factor for ESBL carriage. Thus further studies will be required to draw a meaningful interpretation.

Most of the HPLWH among our study subjects were on ART. Studies related to any association between gut colonization with MDR/ESBL producing Enterobacteriaceae and ART are lacking. However, occasional report stating the emergence of MDR *Mycobacterium tuberculosis* among HIV patients on ART \[[@pone.0212042.ref021]\] may not support the fascinating and novel observation of low gut colonization rate in HPLWH/HIV group in our study, but could, in a way, support the finding of the emergence of drug resistance among the isolates as shown in our study. However, an *in vivo* study conducted earlier, using a mouse model of experimental influenza stated that treatment with antiviral agents improved survival in mice from 0% to 75%, diminishing the occurrence of bacterial colonization, thereby reducing secondary bacterial pneumonia by a yet unknown mechanism \[[@pone.0212042.ref022]\].These findings necessitate further studies to find any link between ART and development of antibiotic resistance vis-a-vis low *in vivo* colonization rate

Considering the risk factors for ESBL-E colonization, it has well been established that gut microbiota are severely impacted and the altered bacterial communities play vital roles, directly or indirectly in disease progression. Previous studies \[[@pone.0212042.ref007]\] identified various risk factors for ESBL-E gut colonization such as; age above 60 years, various co-morbidity conditions, antibiotic use for the prior 4 or 12 months and international travel. In this study, we found close livestock contact and over-the-counter medication (involves both prescription and non-prescription drugs) among healthy subjects as the major risk factors for ESBL colonization. In Nepal and many other neighboring developing countries, people have easy access to all kinds of antibiotics over the counter at pharmacies and private retail shops without any prescription by a registered medical practitioner, which could lead to a calamitous antibiotic resistance situation. The Government of Nepal has designed the National Antibiotic Treatment Guidelines in 2014 \[[@pone.0212042.ref023]\], which is still in course to be implemented. Dispensing practices of antibiotics in community pharmacies was recently studied in central Nepal by Ansari M \[[@pone.0212042.ref024]\], who found that cephalosporins (69.8% cases) were the most frequently dispensed antibiotics, followed by penicillins (68.3%), macrolides (57.1%), fluoroquinolones (49.1%) and sulfonamides (19.3%). Besides, the practice of dispensing antibiotics without prescription and by non-pharmacists were found to be very common.

Recently the most important antibiotic resistance problems identified by the Alliance for the Prudent Use of Antibiotics (APUA) Nepal members (<https://apua.org/nepal/>), included lack of regulation in human, animal and agricultural antibiotic use, justifying the formulation of optimum treatment guidelines along with strict enforcement of \'prescription-only\' laws in the country.

We did not find any significant risk involved with gender, age, ART duration, CD4 count, food habit or international travel. The small sample size in this study could have resulted in reduced power to identify exact risk factors. A larger study may be able to unravel these riddle.

It is well known that ESBL producing isolates often have high rates of co-resistance to commonly used antimicrobials. The results of antimicrobial sensitivity testing revealed that all ESBL producers in this study often co-expressed resistance to many other classes of antibiotics. Most of the isolates from HPLWH group were susceptible to nitrofurantoin and amikacin but showed resistance to cefoxitin, tetracycline and amoxicillin/clavulanic acid. Ciprofloxacin susceptibility was quite lower (41%) in HPLWH group than in the healthy individuals (57.8%). A recent study from Tanzania showed that ESBL producing isolates had high rates of resistance to commonly used antimicrobials \[[@pone.0212042.ref025]\]. Previous studies \[[@pone.0212042.ref026]\] too documented that administration of several antibiotics posed definite risks for multidrug-resistant Enterobacteriaceae colonization. However, it would be of much interest to find out any relationship between antibiotic consumption rates and development of resistance in the gut micro biota of HPLWH and HIV negative individuals, a kind of proposition that warrants investigation in this geographical area.

Genotype prevalence depicted in this study is similar to that projected vide the global reports \[[@pone.0212042.ref002], [@pone.0212042.ref007], [@pone.0212042.ref018]\]. Among *bla*~*CTX-M*~ positive isolates, the most dominant genotype was *bla*~*CTX-M-15*~ (70%) and the dominant bacterial species were *E*. *coli* (83%). Our results were in agreement with previous studies on ESBL-producing Enterobacteriaceae conducted in other places in the Asian subcontinent \[[@pone.0212042.ref002]\]. In addition, Hal Jones C, et al. reported that 44% of the ESBL-E strains collected globally harbored the genes for multiple ESBLs. In this study, 10 (22.2%) of the isolates from HIV positive subjects and 45 (18.6%) from healthy voluntaries possessed two or more ESBL genes. Most of the isolates with multiple ESBL genes had *bla*~*CTX-M-15*~ along with other beta-lactamases, implying that *bla*~*CTX-M-15*~ had the potential to coexist with other beta-lactamases.

The observation of a high prevalence of the CTX-M 15 like genotype, in the present study, further substantiated the earlier notion \[[@pone.0212042.ref002]\] that CTX-Ms were the predominant enzymes among the strains during carriage. This also supported the contention that mobile genetic elements were the cornerstones of the, so-called, current CTX-M pandemic. Plasmids were involved in the intercontinental spread of CTX-M-15, and community outbreaks could be because of strain to strain transmission of plasmids \[[@pone.0212042.ref027]\]. The plausibility of such scenario was further supported by other similar studies from different geographical areas \[[@pone.0212042.ref028], [@pone.0212042.ref029]\] which unanimously agreed that community had a major role to play to act as the main reservoir of CTX-M type ESBL. The presence of this type of enzyme in hospitalized patients could be a secondary consequence and could give rise to subsequent nosocomial outbreaks \[[@pone.0212042.ref030], [@pone.0212042.ref031]\]. Our results not only showed that CTX-M type ESBL has spread to the community, but also that carriage rates were on the rise. This is a major public health concern, though the drivers of this catastrophic spread have not yet been fully elucidated. Future efforts should focus on determining the presence of transferable resistance plasmids through conjugation experiments and incorporating whole-genome sequencing and genomic analysis as additional confirmatory tools to track the spread of these resistance genes within the population \[[@pone.0212042.ref032]\].

The limitation of the present study was PCR products were not subjected to sequencing to confirm the ESBL genotypes. As we screened for the presence of ESBL genes by PCR, we are unable to further speculate whether specific ESBL family variants are stratified within and between the groups.

Conclusion {#sec020}
==========

This study identifies the low fecal carriage rate of ESBL producing bacteria in HPLWH group compared to healthy individuals in western Nepal. The factors responsible for this inverse relationship of HIV status and gut colonization by ESBL-E are unidentified and require further large-scale study. This is the first study in Nepal that has demonstrated a high gut colonization rate by ESBL-E in the community, predominantly of blaCTX-M-15 genotype. We found that livestock contact and over-the-counter medications were significantly associated with a higher ESBL-E carriage rate among healthy subjects. Implementation of strict antibiotic policy and jurisdiction over pharmacy practices are crucial in preventing such colonization.
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